HDAC inhibitors to the rescue in sonic hedgehog medulloblastoma.
作者信息
Becher Oren J
机构信息
Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Malnati Brain Tumor Center and Lurie Cancer Center, Northwestern University, Chicago, Illinois.
出版信息
Neuro Oncol. 2019 Sep 6;21(9):1091-1092. doi: 10.1093/neuonc/noz115.
Abstract
摘要
相似文献
1
HDAC inhibitors to the rescue in sonic hedgehog medulloblastoma.
Neuro Oncol. 2019 Sep 6;21(9):1091-1092. doi: 10.1093/neuonc/noz115.
2
A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Neuro Oncol. 2019 Sep 6;21(9):1150-1163. doi: 10.1093/neuonc/noz089.
3
HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
Neuro Oncol. 2021 Feb 25;23(2):173-174. doi: 10.1093/neuonc/noaa292.
4
Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene.
Cell Cycle. 2010 Jun 1;9(11):2047-8. doi: 10.4161/cc.9.11.11860.
5
Targeted therapy done right: Direct sonic hedgehog inhibition for sonic hedgehog medulloblastoma.
Neuro Oncol. 2024 Apr 5;26(4):623-624. doi: 10.1093/neuonc/noae018.
6
Blood-Brain Barrier Breakdown Determines Differential Therapeutic Outcome in Genetically Diverse Forms of Medulloblastoma.
Cancer Cell. 2016 Apr 11;29(4):427-429. doi: 10.1016/j.ccell.2016.03.024.
7
SHH inhibitors for the treatment of medulloblastoma.
Expert Rev Neurother. 2015;15(7):763-70. doi: 10.1586/14737175.2015.1052796. Epub 2015 May 31.
8
Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
Cancer Res. 2015 Jan 1;75(1):134-46. doi: 10.1158/0008-5472.CAN-13-3629. Epub 2014 Nov 12.
9
Medulloblastoma: signalling a change in treatment.
Lancet Oncol. 2004 Apr;5(4):209-18. doi: 10.1016/S1470-2045(04)01424-X.
10
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
PLoS One. 2016 Mar 3;11(3):e0150836. doi: 10.1371/journal.pone.0150836. eCollection 2016.
引用本文的文献
1
Stem Cells in Cancer: From Mechanisms to Therapeutic Strategies.
Cells. 2025 Apr 3;14(7):538. doi: 10.3390/cells14070538.
2
Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas.
Cancer Gene Ther. 2023 Aug;30(8):1105-1113. doi: 10.1038/s41417-023-00616-z. Epub 2023 Apr 11.
3
Multidisciplinary Management of Medulloblastoma: Consensus, Challenges, and Controversies.
Methods Mol Biol. 2022;2423:215-235. doi: 10.1007/978-1-0716-1952-0_19.
4
NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Int J Mol Sci. 2021 May 31;22(11):5907. doi: 10.3390/ijms22115907.
5
The multilayer community structure of medulloblastoma.
iScience. 2021 Mar 26;24(4):102365. doi: 10.1016/j.isci.2021.102365. eCollection 2021 Apr 23.
本文引用的文献
1
A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Neuro Oncol. 2019 Sep 6;21(9):1150-1163. doi: 10.1093/neuonc/noz089.
2
Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor.
Oncotarget. 2017 Sep 1;8(41):69295-69302. doi: 10.18632/oncotarget.20619. eCollection 2017 Sep 19.
3
Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.
Neuro Oncol. 2017 Oct 19;19(11):1542-1552. doi: 10.1093/neuonc/nox109.
4
Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma.
Sci Rep. 2017 Mar 9;7:44079. doi: 10.1038/srep44079.
5
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
J Clin Oncol. 2015 Aug 20;33(24):2646-54. doi: 10.1200/JCO.2014.60.1591. Epub 2015 Jul 13.
6
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Cancer Cell. 2014 Mar 17;25(3):393-405. doi: 10.1016/j.ccr.2014.02.004.
7
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
Acta Neuropathol. 2012 Apr;123(4):473-84. doi: 10.1007/s00401-012-0958-8. Epub 2012 Feb 23.
8
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.
9
Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.
J Neurooncol. 2006 Sep;79(3):259-70. doi: 10.1007/s11060-006-9142-0. Epub 2006 Apr 28.
10
Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.
Nature. 2000 Aug 31;406(6799):1005-9. doi: 10.1038/35023008.
Zotero 插件